Medclair AB (NGM:MCLR) Current Deferred Revenue: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:MCLR Medclair AB NGM:MCLR
68 GF Score
Price kr2.94
GF Value kr2.36
Valuation Modestly Overvalued
View Full Analysis

What is Medclair AB Current Deferred Revenue?

Medclair AB NGM:MCLR -0.68% 68 Current Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 68/100 and a GF Value™ of kr2.36 (Modestly Overvalued).

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Medclair AB's current deferred revenue for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Medclair AB Current Deferred Revenue Related Terms

Medclair AB Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Medclair AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medclair AB Current Deferred Revenue Chart

Medclair AB Annual Data
Trend Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medclair AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGM:MCLR
68GF Score
Medclair AB NGM:MCLR
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of kr0.00 Mil mean?
Medclair AB (NGM:MCLR) has a Current Deferred Revenue of kr0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Medclair AB and its competitors.
Is Medclair AB's Current Deferred Revenue too high?
Medclair AB's current Current Deferred Revenue is kr0.00 Mil. Overall, Medclair AB has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Current Deferred Revenue compare to ABT and SYK?
Medclair AB's Current Deferred Revenue of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Medclair AB and its competitors. Medclair AB's current Current Deferred Revenue is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.36, compared to a current price of kr2.94 — trading 24.6% above its estimated fair value. The current Current Deferred Revenue is kr0.00 Mil. Medclair AB's overall GF Score™ is 68/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Current Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medclair AB (NGM:MCLR) Overvalued in 2026?

Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued. The current stock price of kr2.94 is trading 24.6% above its estimated GF Value™ of kr2.36. GuruFocus considers Medclair AB to be Modestly Overvalued.

Key valuation signals for NGM:MCLR:

  • Current Deferred Revenue: kr0.00 Mil
  • GF Value™: kr2.36 vs. price of kr2.94 (24.6% above fair value)
  • GF Score™: 68/100

No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medclair AB Business Description

Address Fraktflygargatan 1, Stockholm, SWE, 128 30
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
68GF Score

Get the complete analysis for NGM:MCLR

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.94
Price
kr2.36
GF Value